The estimated Net Worth of Christopher K. Murray is at least $7.45 Million dollars as of 7 March 2024. Christopher Murray owns over 2,521 units of Blueprint Medicines Corp stock worth over $2,930,316 and over the last 7 years he sold BPMC stock worth over $981,043. In addition, he makes $3,539,270 as Senior Vice President and Technical Operations at Blueprint Medicines Corp.
Christopher has made over 11 trades of the Blueprint Medicines Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,521 units of BPMC stock worth $228,629 on 7 March 2024.
The largest trade he's ever made was exercising 5,000 units of Blueprint Medicines Corp stock on 28 February 2024 worth over $270,650. On average, Christopher trades about 1,435 units every 86 days since 2017. As of 7 March 2024 he still owns at least 33,853 units of Blueprint Medicines Corp stock.
You can see the complete history of Christopher Murray stock trades at the bottom of the page.
Dr. Christopher K. Murray Ph.D. serves as Senior Vice President, Technical Operations of the Company. He has served as our senior vice president, technical operations. Dr. Murray served as vice president, technical operations at ARIAD Pharmaceuticals, Inc., or ARIAD. In this role, Dr. Murray oversaw all aspects of commercial and clinical manufacturing, supply chain and logistics, process development, quality control and analytical chemistry for ARIAD’s approved products and product candidates, including Iclusig® (ponatinib) and Alunbrig® (brigatinib). From 2004 to December 2013, Dr. Murray held multiple roles of increasing responsibility at ARIAD related to process development, manufacturing and clinical supply. Prior to joining ARIAD, Dr. Murray served in various positions with Allos Therapeutics, Inc. and Hauser Inc. related to clinical and commercial manufacturing and supply of active pharmaceutical ingredient. Dr. Murray holds a B.S. from Hope College with a major in chemistry and a Ph.D. in chemistry from the University of Chicago.
As the Senior Vice President and Technical Operations of Blueprint Medicines Corp, the total compensation of Christopher Murray at Blueprint Medicines Corp is $3,539,270. There are 2 executives at Blueprint Medicines Corp getting paid more, with Jeffrey Albers having the highest compensation of $9,362,370.
Christopher Murray is 57, he's been the Senior Vice President and Technical Operations of Blueprint Medicines Corp since 2017. There are 7 older and 21 younger executives at Blueprint Medicines Corp. The oldest executive at Blueprint Medicines Corp is Mark Goldberg, 65, who is the Independent Director.
Christopher's mailing address filed with the SEC is C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 9 years, insiders at Blueprint Medicines Corp have traded over $126,865,732 worth of Blueprint Medicines Corp stock and bought 131,110 units worth $2,599,105 . The most active insiders traders include Llc Fmr, Kevin P Starr, and Lonnel Coats. On average, Blueprint Medicines Corp executives and independent directors trade stock every 12 days with the average trade being worth of $1,362,195. The most recent stock trade was executed by Jeffrey W. Albers on 9 September 2024, trading 19,702 units of BPMC stock currently worth $1,685,900.
blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
Blueprint Medicines Corp executives and other stock owners filed with the SEC include: